Table 1.

Comparisons of different targeted cancer therapies

	PROTAC	CRISPR/Cas9	RNA interfering	small-molecule inhibitor	monoclonal antibody
Requirement of active sites	No	No	No	Yes	Yes
Elimination of pathogenic proteins	Yes	Yes	Yes	No	No
Undruggable targets	Yes	Yes	Yes	No	Yes
Tissue penetration	Moderate	Poor	Poor	Yes	Poor
Intracellular targets	Yes	Yes	Yes	Yes	No
Systemic delivery	Yes	Poor	No	Yes	Yes
Catalytic mechanism of action	Yes	Yes	Yes	No	No
Route of administration	PO/IV/SC	IV	IV/SC	PO/IV/SC	IV/SC

Note: IV intravenous injection, PO peros, SC Subcutaneous injection